Chargement en cours...
Everolimus Directly Suppresses Insulin Secretion Independently of Cell Growth Inhibition
Everolimus, an orally administered mammalian target of rapamycin inhibitor, has been widely used as an immunosuppressant and an anticancer agent. Whereas everolimus can control recurrent hypoglycemia in patients with insulinoma, possibly through tumor regression and/or the direct inhibition of insul...
Enregistré dans:
| Publié dans: | J Endocr Soc |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Endocrine Society
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6007247/ https://ncbi.nlm.nih.gov/pubmed/29942923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2017-00475 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|